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OBJECTIVES We sought to test the hypothesis that there is a relationship between inflammation and the
prothrombotic state in atrial fibrillation (AF).
BACKGROUND Atrial fibrillation is associated with a prothrombotic or hypercoagulable state, which may
contribute to an increased risk of stroke and thromboembolism. Inflammation may be
involved in the pathogenesis of AF, but the role of inflammation in the pathophysiology of
the prothrombotic state of AF has not been studied in detail, despite evidence of a link
between inflammation and arterial atherothrombotic disorders.
METHODS We measured plasma indexes of inflammation (C-reactive protein [CRP] and interleukin-6
[IL-6]) and the prothrombotic state, including markers of platelet activation (soluble
P-selectin), endothelial damage/dysfunction (von Willebrand factor), the coagulation cascade
(tissue factor [TF], fibrinogen), and indexes of blood rheology (plasma viscosity, plasma
fibrinogen, and hematocrit) in 106 patients with chronic AF and 41 healthy control subjects
included in a cross-sectional analysis.
RESULTS Compared with controls, AF patients had higher levels of IL-6 (p  0.034), CRP (p 
0.003), TF (p  0.019), and plasma viscosity (p  0.045). Plasma IL-6 levels were higher
among AF patients at “high” risk of stroke (p  0.003). After adjusting for potential
confounding clinical variables (e.g., vascular disease), AF remained significantly associated
with a raised logarithmic transformation (log) of TF (p 0.04), but the relationships between
AF and log IL-6, log CRP, and plasma viscosity became nonsignificant. Among AF patients,
log TF (p  0.001) and high stroke risk (p  0.003) were independent associates of log IL-6
(adjusted r2  0.443), whereas log fibrinogen (p  0.001) and plasma viscosity (p  0.04)
were independent associates of log CRP (adjusted r2  0.259).
CONCLUSIONS Increased plasma IL-6, CRP, and plasma viscosity support the case for the existence of an
inflammatory state among “typical” populations with chronic AF. These indexes of inflam-
mation are related to indexes of the prothrombotic state and may be related to the clinical
variables of the patients (underlying vascular disease and co-morbidities), rather than simply
to the presence of AF itself. (J Am Coll Cardiol 2004;43:2075–82) © 2004 by the
American College of Cardiology Foundationtrial fibrillation (AF) is a major cause of morbidity and Inflammatory mechanisms, including C-reactive protein
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Cortality from stroke and thromboembolism (1), usually
ue to embolization of thrombus formed within the fibril-
ating left atrium and its appendage (2). Atrial fibrillation is
ssociated with a prothrombotic or hypercoagulable state
3), with evidence of abnormal hemostasis, endothelial
amage/dysfunction, and platelet activation (4–24). Fur-
hermore, certain indexes of the prothrombotic state have
een associated with an increased risk of left atrial append-
ge thrombus (25) and spontaneous echo contrast (26),
uggesting an increased risk of thromboembolism (27), and
ay even predict future stroke and cardiovascular morbid-
ty/mortality in those with AF (28). The high levels of these
arkers in AF may be due to AF itself (6) or the presence
f additional cardiovascular co-morbidities (29,30), but the
athophysiologic mechanisms underlying the prothrom-
otic state in AF remain poorly understood.
From the Haemostasis Thrombosis and Vascular Biology Unit, University Depart-
ent of Medicine, City Hospital, Birmingham, England. This study was supported
y the Dowager Countess Eleanor Peel Trust and the Sandwell and West Birming-
am Hospitals NHS Trust Research and Development Program for the Haemostasis
hrombosis and Vascular Biology Unit.lManuscript received November 4, 2003; accepted November 25, 2003.CRP) and interleukin-6 (IL-6), are suspected to play a role
n arterial thrombogenesis (for example, in myocardial
nfarction [31–33]), but their association with the pro-
hrombotic state of AF has not been studied in detail,
espite reports of increased CRP levels in AF (34). To test
he hypothesis that inflammation might be associated with
he prothrombotic state of AF, we measured plasma indexes
f inflammation (CRP and IL-6), platelet activation (solu-
le P-selectin [sP-sel]), endothelial damage/dysfunction
von Willebrand factor [vWF]), the coagulation cascade
tissue factor [TF], fibrinogen), and indexes of blood rheo-
ogy (plasma viscosity, plasma fibrinogen, and hematocrit)
n 106 patients with chronic AF and 41 healthy control
ubjects included in a cross-sectional analysis.
ETHODS
atients. We studied 106 outpatients (67 men; mean
SD] age 69  10 years) with chronic, permanent
onvalvular AF who were attending our specialist AF clinic.
hronic AF was confirmed by electrocardiography on ateast two separate occasions (6 weeks apart). We excluded
a
m
h
o
i
i
m
p
d
t
a
(
B
a
m
n
t
r
m
d
r
a
s
a
B
w
a
p
p
4
A
M
f
(
a
a
i
b
(
t
c
F
n
H
c
b
b
u
L
t
u
P
s
a
o
p
r
a
i
m
p
t
p
m
m
t
c
e
v
s
t
a
s
p
A
s
R
A
p
c
p
h
l
w
I
p
p
n
r
p
w
t
u
L
e
p
c

2076 Conway et al. JACC Vol. 43, No. 11, 2004
Inflammation in AF June 2, 2004:2075–82ny patients with hematologic, renal, or hepatic impair-
ent; inflammatory, neoplastic disorders; and those who
ad a recent (3 months) myocardial infarction or stroke,
r acute AF precipitated by thyrotoxicosis or any acute
nfection. Patients who consumed regular nonsteroidal anti-
nflammatory drugs, corticosteroids, or hormone replace-
ent therapy were also excluded, as were post-cardioversion
atients. A “high” and “low to moderate” risk of stroke was
efined according to prospectively validated risk stratifica-
ion criteria (35). “Lone” AF was defined as AF in the
bsence of risk factors, with a normal electrocardiogram
apart from the AF), chest X-ray, and echocardiography.
lood results in patients with AF were compared with 41
ge- and gender-comparable healthy control subjects (25
en; mean [SD] age 67  10 years), which consisted of
ormal subjects recruited from healthy hospital staff, rela-
ives of the patients, and those attending the hospital for
outine senile cataract surgery. Control subjects were nor-
otensive and in sinus rhythm, with no clinical evidence of
isease, on careful history, examination, and routine labo-
atory tests. Written, informed consent was obtained from
ll participants in the study, and ethical approval for the
tudy was obtained from the West Birmingham Research
nd Ethics Committee.
lood sampling and laboratory analysis. Blood samples
ere drawn atraumatically and without stasis into EDTA
nd trisodium citrate (0.011 mol/l) tubes. The citrated
lasma was stored at 70°C until batch analyses. Platelet-
oor plasma fractions were obtained by centrifugation at
°C for 20 min at 3,000 rpm within 1 h of collection.
liquots were stored at 70°C to allow batch analysis.
easurements of IL-6, sP-sel, vWF, and TF were per-
ormed using ELISA with reagents from R&D Systems
Abingdon, United Kingdom) (for IL-6, sP-sel, and TF)
nd Dako-Patts (Ely, United Kingdom ) (for vWF). Intra-
ssay coefficients of variation for all ELISAs were 5%;
nterassay variances were10%. Plasma CRP was measured
y a high-sensitivity latex particle turbidimetric assay
Wako, Neuss, Germany). The lower limit of sensitivity of
his method was 0.01 mg/dl, and the intra- and interassay
oefficients of variation were 2.2% and 5.0%, respectively.
ibrinogen was measured using a modified Clauss tech-
ique, using a coagulometer and thrombin from Pacific
aemostasis (Huntersville, North Carolina).
The EDTA samples were processed within 1 h of
ollection. Hematocrit was measured using an automated
Abbreviations and Acronyms
AF  atrial fibrillation
CRP  C-reactive protein
IL-6  interleukin-6
sP-sel  soluble P-selectin
TF  tissue factor
vWF  von Willebrand factorlood count machine (Advia 120, Bayer Diagnostics, New- wury, United Kingdom). Plasma viscosity was measured
sing a Coulter viscometer II (Coulter Electronics Ltd.,
uton, United Kingdom). None of the blood samples from
he participants included in this study have been previously
sed for research studies from our department.
ower calculations and statistical analysis. We hypothe-
ized that patients with AF would have levels of TF
pproximately 0.4 of a standard deviation higher than those
f subjects in sinus rhythm (5). To achieve this with a 1-beta
ower of 0.80 and p  0.05, 40 subjects per group are
equired. In view of our measurement of multiple indexes
nd to minimize the risk of a type II error, we recruited far
n excess of this number of AF patients.
Continuous data are expressed as the mean value SD or
edian value (interquartile range). Differences between
atients and controls were evaluated using the two-sample t
est, Mann-Whitney U test, and chi-square test, as appro-
riate. Linear regression analysis was performed for each
arker associated with AF on univariate analysis (nonpara-
etrically distributed variables examined after logarithmic
ransformation [log]) to adjust for possible confounding by
linical variables associated with AF. Correlations were
valuated using Spearman’s rank correlation method, in
iew of the skewed distributions of CRP, IL-6, fibrinogen,
P-sel, and TF. Stepwise linear regression analyses were
hen performed (nonparametrically distributed variables ex-
mined after log transformation), entering all variables
ignificantly associated with the marker on univariate com-
arison, to identify independent associates of each marker in
F. A value of p  0.05 was considered as statistically
ignificant.
ESULTS
s expected, there were significant differences between
atients and controls in terms of therapy and additional
ardiovascular co-morbidities commonly found among AF
atients (Table 1). Of the AF patients, 55 (52%) were at
igh risk of future stroke, with the remaining 51 (48%) at
ow to moderate risk. Only 28 (26%) of the 106 patients
ith AF could be classified as lone AF.
Compared with controls, AF patients had higher levels of
L-6 (p  0.034), CRP (p  0.003), TF (p  0.019), and
lasma viscosity (p  0.045) (Table 1). After adjusting for
otential confounding clinical variables, AF remained sig-
ificantly associated with raised log TF (p  0.04), but the
elationships between AF and log CRP, log IL-6, and
lasma viscosity became nonsignificant (Table 2). There
ere no significant relationships between antithrombotic
herapy use (aspirin, warfarin) and our research indexes on
nivariate analysis (all p  0.1, data not shown).
one AF patients versus controls. In addition to the
xpected differences in therapy, systolic and diastolic blood
ressure was lower among lone AF patients than among
ontrols. Plasma TF was higher among lone AF patients (p
0.047), but no other statistically significant relationships
ere seen (all p  0.05) (Table 3).
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June 2, 2004:2075–82 Inflammation in AFigh- versus low to moderate risk in AF patients. By
efinition, high-risk AF patients were older and less likely to
e male than those at low to moderate risk, and this high-risk
roup included all patients with a previous stroke or heart
ailure (Table 4). These high-risk patients had higher plasma
L-6 levels (p  0.003) (Fig. 1), but lower hematocrit (p 
.006), than those at low to moderate risk (Table 4).
orrelations and multivariate analyses among AF
atients. Log TF (p  0.001) and high stroke risk (p 
.003) were independent associates of log IL-6 (adjusted r2
0.443). The correlation between IL-6 and TF is illus-
rated in Figure 2. Log fibrinogen (p  0.001) and plasma
iscosity (p 0.04) were independent associates of log CRP
adjusted r2  0.259). The correlations between CRP and
brinogen and vWF are shown in Figure 3, although vWF
as not an independent associate of CRP. We found no
ignificant correlations between plasma levels of IL-6 and
RP among either AF patients (r  0.125, p  0.107) or
ontrols (r  0.246, p  0.065).
Log IL-6 (p  0.001) and hematocrit (p  0.014) were
ndependent associates of log TF (adjusted r2 0.385). Plasma
Table 1. Clinical Characteristics and Plasma M
State in Patients With Atrial Fibrillation and H
AF P
(n 
Age (yrs) 69
Male 67 (6
Hypertension 56 (5
Heart failure 23 (2
Diabetes 16 (1
Previous stroke 18 (1
Ischemic heart disease 29 (2
Cigarette smokers 23 (2
Systolic blood pressure (mm Hg) 138
Diastolic blood pressure (mm Hg) 81
Cholesterol (mmol/l) 5.2
Antithrombotic therapy
None 15 (1
Aspirin 12 (1
Warfarin 79 (7
Hematocrit (%) 43
Plasma viscosity (mPa) 1.73
von Willebrand factor (IU/dl) 132
Fibrinogen (g/l) 2.57 (2
Tissue factor (pg/ml) 115 (8
Soluble P-selectin (ng/ml) 54 (4
Interleukin-6 (pg/ml) 24 (3
C-reactive protein (mg/dl) 0.27 (0
Data are expressed as the mean value  SD, median value (
AF  atrial fibrillation.
able 2. Effect of Atrial Fibrillation on Levels of Plasma CRP, I
Expected Change in Log
CRP (g/dl)
Expected Chan
IL-6 (pg
trial fibrillation 0.23 (0.04–0.41), p  0.02 0.30 (0.03–0.57),
trial fibrillation,
adjusted*
0.15 (0.22–0.39), p  0.57 0.41 (0.02–0.83
Adjusted for hypertension, diabetes mellitus, previous stroke, heart failure, ischemic
Log CRP  logarithmic transformation of plasma C-reactive protein (CRP); Logransformation of tissue factor (TF).iscosity (p  0.002) was the only independent associate of
WF (adjusted r2  0.135). Log CRP (p  0.001) was the
nly independent associate of log fibrinogen (adjusted r2 
.223). Log TF (p  0.001), vWF (p  0.038), and plasma
iscosity (p 0.025) were independent associates of log sP-sel
adjusted r2  0.279). Heart failure (p  0.038), log CRP (p
0.022), and vWF (p  0.009) were independent associates
f plasma viscosity (adjusted r2  0.240). Current smoking (p
0.012) and high risk (p  0.004) were independent
ssociates of hematocrit (adjusted r2  0.126).
All the independent associations previously listed were
ositive associations, except for the relationships between
ematocrit and TF and hematocrit and high risk, which
ere inverse associations. Other correlations were not sta-
istically significant (data not shown).
ISCUSSION
e found increased plasma levels of IL-6 and CRP and
aised plasma viscosity among AF patients compared with a
atched healthy control population, suggesting the pres-
nce of inflammation among our cases, although the rela-
rs of Inflammation and the Prothrombotic
hy Control Subjects
ts
)
Healthy Controls
(n  41) p Value
67  10 0.28
25 (61%) 0.80
0 0.001
0 0.001
0 0.008
0 0.005
0 0.001
4 (10%) 0.10
138  13 0.91
81  7 0.70
5.5  0.9 0.25
41 (100%) 0.001
0
0
43  5 0.43
3 1.68  0.10 0.045
125  21 0.14
.28) 2.68 (2.19–3.34) 0.61
) 95 (75–120) 0.019
50 (38–65) 0.70
3 (3–62) 0.034
.50) 0.13 (0.07–0.24) 0.003
uartile range), or number (%) of subjects.
TF and Plasma Viscosity: Linear Regression Analyses
Log Expected Change in Log
TF (pg/ml)
Expected Change in
Plasma Viscosity (mPa)
.03 0.12 (0.02–0.21), p  0.02 0.05 (0.00–0.10), p  0.05
0.06 0.17 (0.01–0.33), p  0.04 0.00 (0.07–0.08), p  0.84
disease, and antithrombotic therapy use.
logarithmic transformation of plasma interleukin-6 (IL-6); Log TF  logarithmicarke
ealt
atien
106
 10
3%)
3%)
2%)
5%)
7%)
7%)
2%)
 19
 11
 1.1
4%)
1%)
5%)
 5
 0.1
 26
.25–3
5–176
1–65)
–77)
.11–0
interqL-6,
ge in
/ml)
p  0
), p 
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Inflammation in AF June 2, 2004:2075–82ionships between inflammatory markers and AF became
onsignificant after adjusting for potential confounding
linical variables. However, plasma IL-6 levels were signif-
cantly higher among AF patients at high risk of stroke. No
orrelations were found between plasma levels of IL-6 and
RP among AF patients, but correlations were found
etween both of these inflammatory markers and certain
Table 4. Clinical Characteristics and Plasma M
State in Atrial Fibrillation: Relationship to Str
High
(n 
Age (yrs) 71 
Male 27 (49%
Hypertension 32 (58%
Heart failure 23 (42%
Diabetes 7 (13%
Previous stroke 18 (33%
Ischemic heart disease 17 (31%
Cigarette smokers 13 (24%
Systolic blood pressure (mm Hg) 141 
Diastolic blood pressure (mm Hg) 80 
Antithrombotic therapy
None 9 (16%
Aspirin 6 (11%
Warfarin 40 (73%
Cholesterol (mmol/l) 5.2 
Hematocrit (%) 41 
Plasma viscosity (mPa) 1.75 
von Willebrand factor (IU/dl) 136 
Fibrinogen (g/l) 2.69 (2.3
Tissue factor (pg/ml) 135 (90–
Soluble P-selectin (ng/ml) 55 (45–
Interleukin-6 (pg/ml) 37 (14–
C-reactive protein (mg/dl) 0.29 (0.1
Table 3. Clinical Characteristics and Plasma M
State: Lone Atrial Fibrillation Patients Versus
Lo
Pa
(n
Age (yrs) 68
Male 16 (5
Cigarette smokers 6 (2
Systolic blood pressure (mm Hg) 129
Diastolic blood pressure (mm Hg) 76
Antithrombotic therapy
None 5 (1
Aspirin 5 (1
Warfarin 18 (6
Hematocrit (%) 44
Plasma viscosity (mPa) 1.73
Cholesterol (mmol/l) 5.8
von Willebrand factor (IU/dl) 132
Fibrinogen (g/l) 2.60 (2
Soluble P-selectin (ng/ml) 59 (4
Tissue factor (pg/ml) 108 (9
Interleukin-6 (pg/ml) 18 (3
C-reactive protein (mg/dl) 0.28 (0
Data are expressed as the mean value  SD, median value (
AF  atrial fibrillation.Data are expressed as the mean value  SD, median value (interqrothrombotic plasma markers. Notably, we found raised
lasma levels of TF in AF even after adjustment for
onfounders and among lone AF patients, and TF levels
trongly correlated with IL-6 levels among patients.
Intravascular thrombogenesis is responsible for much of
he mortality and morbidity of cardiovascular disease, but
he mechanisms behind thrombogenesis remain poorly un-
rs of Inflammation and the Prothrombotic
isk
Low to Moderate
Risk (n  51) p Value
67  10 0.042
40 (78%) 0.002
24 (47%) 0.252
0 0.001
9 (18%) 0.480
0 0.001
12 (24%) 0.394
10 (20%) 0.615
134  17 0.100
82  11 0.469
0.794
6 (12%)
6 (12%)
39 (76%)
5.3  1.1 0.584
44  4 0.006
1.71  0.13 0.250
127  26 0.066
6) 2.53 (2.22–3.34) 0.447
100 (85–135) 0.105
53 (36–68) 0.436
7 (3–51) 0.003
6) 0.25 (0.10–0.43) 0.326
rs of Inflammation and the Prothrombotic
thy Control Subjects in Sinus Rhythm
)
Healthy
Controls
(n  41) p Value
67  10 0.827
25 (61%) 0.750
4 (10%) 0.190
138  13 0.011
81  7 0.011
41 (100%) 0.001
0
0
43  5 0.817
2 1.68  0.10 0.121
5.5  0.9 0.259
125  21 0.212
.50) 2.68 (2.19–3.34) 0.953
) 50 (38–65) 0.465
0) 95 (75–120) 0.047
3 (3–62) 0.157
.45) 0.13 (0.07–0.24) 0.056
uartile range), or number (%) of subjects.arke
oke R
Risk
55)
10
)
)
)
)
)
)
)
21
12
)
)
)
1.2
5
0.12
25
2–3.2
210)
65)
112)
0–0.5arke
Heal
ne AF
tients
 28
 13
7%)
1%)
 15
 8
8%)
8%)
4%)
 4
 0.1
 1.0
 24
.18–3
0–73
1–14
–66)
.08–0
interquartile range), or number (%) of subjects.
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June 2, 2004:2075–82 Inflammation in AFerstood. Recently, increasing attention has focused on
ossible links between inflammatory and thrombotic pro-
esses, particularly in the setting of coronary atherothrom-
otic occlusion (31–33). Despite evidence that both IL-6
nd CRP may predict such events (33), there have been few
tudies examining the possible role of inflammatory medi-
tors in the prothrombotic state of AF.
Figure 1. Relationship between plasma interleukin-6 (I
igure 2. Correlation between plasma levels of interleukin-6 (IL-6) and T
lasma IL-6; Log TF  logarithmic transformation of tissue factor.The hypothesis that inflammation may play a role in the
athogenesis of AF was initially suggested by the temporal
elationship between elevation in circulating IL-6 and CRP
fter cardiac surgery and the onset of postoperative arrhyth-
ias (36). Inflammatory infiltrates, necrosis, and fibrosis
ave also been demonstrated in atrial tissue from patients
ith lone AF (37), although intra-atrial inflammatory
and stroke risk stratification in atrial fibrillation (AF).
trial fibrillation (AF) patients. Log IL-6  logarithmic transformation ofF in a
F
c
c
o
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Inflammation in AF June 2, 2004:2075–82igure 3. (A) Correlation between plasma levels of C-reactive protein (CRP) and fibrinogen in atrial fibrillation (AF) patients. Spearman correlation
oefficient: r  0.415, p  0.001. (B) Correlation between plasma levels of CRP and von Willebrand factor (vWF) in AF patients. Spearman
orrelation coefficient: r  0.380, p  0.001. Log CRP  logarithmic transformation of plasma CRP. Log fibrinogen  logarithmic transformation
f fibrinogen.
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June 2, 2004:2075–82 Inflammation in AFytokines are not apparent in chronic AF complicating
tructural heart disease (38). Raised circulating inflamma-
ory indexes in AF may therefore not necessarily reflect local
olecular changes in the atrial wall, but still might have
mplications for a prothrombotic state. In support of an
nflammatory hypothesis, two studies have found raised
irculating levels of CRP in AF (34,39), leading the authors
f the larger study to suggest that CRP might be important
n the prothrombotic state in AF via stimulation of TF
roduction from monocytes (34,40). However, raised levels
f IL-6 and CRP in AF may simply be secondary to
nderlying atherosclerosis, as the relationships between the
nflammatory markers and AF in the present study became
onsignificant after adjusting for potential confounding
linical variables (mostly classic atherosclerosis risk factors
nd/or associates).
We were surprised to find no significant correlation
etween IL-6 and CRP among our AF patients, despite
aised levels of both markers. Although factors such as
ultiple drug therapy might be partly responsible for
uppression of the relationship between these markers in the
F group, we also found no such correlation among the
ontrol group. To validate our assay results, we had concur-
ently analyzed plasma samples from patients admitted to
ur hospital with acute sepsis/infection, among whom we
ound the anticipated (strong) correlation between IL-6 and
RP (r  0.760, p  0.001; data not shown). Therefore, it
s possible that while IL-6 may be involved in an increase in
RP in acute inflammation, it may play a lesser role in
etermining CRP levels in low-grade, chronic inflammatory
tates (such as our AF cohort) and in the “normal” popula-
ion, with perhaps a greater influence of other factors/
ytokines on CRP in these situations.
Atrial fibrillation has previously been shown to be asso-
iated with evidence of a prothrombotic state (3). Certain of
hese markers have also been demonstrated to predict the
resence of left atrial thrombus (25) or spontaneous echo
ontrast (26), or to predict future cardiovascular mortality/
orbidity (including stroke) in AF (28). In our current
tudy, TF was the only prothrombotic marker significantly
aised in AF patients. Tissue factor is responsible for the
nitiation of the coagulation cascade, via activation of factor
II to factor VIIa, eventually leading to formation of a
brin-rich thrombus. Furthermore, TF is expressed by both
he vascular endothelium and circulating monocytes, al-
hough the primary source of TF in the plasma is unclear
41). In an earlier study (5), we found that raised plasma
evels of TF among AF patients strongly correlated with
lasma levels of vascular endothelial growth factor, perhaps
upporting an endothelial origin of TF, whereas the present
tudy finding of a strong correlation with the inflammatory
ytokine IL-6 may support cytokine-driven TF production
rom monocytes (42). However, despite the hypothesis by
hung et al. (34), no relationship was seen between CRP
nd TF in this study, although CRP did significantly
orrelate with fibrinogen and plasma viscosity (plus vWFnd sP-sel on univariate analysis; data not shown), support-
ng a relationship between CRP and the prothrombotic
tate in AF.
tudy limitations. Our study is limited by the cross-
ectional design, and we are thus unable to examine tem-
oral relationships between inflammatory and prothrom-
otic indexes, or the effect of these indexes on clinical
utcome. Furthermore, the individuals in our study had
stablished chronic AF, and alteration of antithrombotic
herapy for the purposes of the study or the introduction of
arfarin for several weeks among healthy controls would
ot have been ethical. However, we have attempted to
inimize the risk of confounding by adjustment for anti-
hrombotic therapy in the case-control comparison, and no
ignificant relationships to our research indexes were found.
ndeed, antithrombotic therapy in AF patients has previ-
usly been shown to have no significant effect on plasma
evels of IL-6 (43), fibrinogen (14), vWF, or sP-sel (14,29),
hereas evidence for the effects of antithrombotic therapy
n other inflammatory and prothrombotic indexes remains
nconclusive (44–47). Another limitation of our study is
hat the design does not allow us to establish or refute an
ndependent effect of AF itself or of associated vascular
isease on our markers, although this was not the primary
im of our study. A study of a much larger AF cohort with
elatively even proportions of each risk factor, plus a second
ontrol group in sinus rhythm but with risk factors, would
e needed to conclusively determine the independent con-
ribution of AF.
Accepting these limitations, our finding of elevated
lasma levels of CRP, IL-6, and TF among a typical
opulation of AF patients, with significant correlations
etween inflammatory and prothrombotic indexes, is con-
istent with a potential role for inflammation in the pro-
hrombotic state of AF. However, the inflammatory state in
F may be related to the clinical variables of the patients
e.g., underlying vascular disease and co-morbidities), rather
han simply to the presence of AF itself. Indeed, cytokines
ther than IL-6 may influence the inflammatory state in AF
nd deserve investigation.
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